H.C. Wainwright analyst Sean Lee raised the firm’s price target on Verastem (VSTM) to $14 from $10 and keeps a Buy rating on the shares after the company’s avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM: